Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Fineline Cube Jan 20, 2026
Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Fineline Cube Jan 20, 2026
Company Drug

HutchMed Initiates China Bridging Study for Tazverik in Follicular Lymphoma

Fineline Cube Aug 2, 2022

HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a bridging study for Tazverik (tazemetostat)...

Company Deals

Hainan Shuangcheng to Transfer Triptorelin Assets to Chongqing Lummy for USD 4.7M

Fineline Cube Aug 2, 2022

Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) will transfer all tangible and intangible assets and...

Company Drug

Eccogene Receives FDA Approval for ECC4703 Phase I Study in NASH and Dyslipidemia

Fineline Cube Aug 2, 2022

Shanghai-based biopharmaceutical company Eccogene announced it has received approval from the U.S. Food and Drug...

Company

HutchMed’s H1 2022 Oncology Sales Surge 82% on Strong Product Performance

Fineline Cube Aug 2, 2022

China-based biopharma HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) reported strong financial results for the...

Company Drug

Lion TCR Enrolls First Patient in LioCyx-M004 Study for HBV-Related Liver Cancer

Fineline Cube Aug 2, 2022

Singapore-based clinical-stage biotech Lion TCR announced the enrollment of the first subject in a clinical...

Company Drug

Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review

Fineline Cube Aug 2, 2022

Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has...

Company Deals

OriginCell Therapeutics Raises USD 120M in Series B for Tumor Immunotherapy Pipeline

Fineline Cube Aug 1, 2022

OriginCell Therapeutics, a Shanghai-based tumor immunotherapy specialist, reportedly raised over USD 120 million in a...

Company Deals

Fosun Pharma to Hike Aitrox Stake to 72.63% for USD 61M

Fineline Cube Aug 1, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) plans to increase its ownership...

Company Deals

GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline

Fineline Cube Aug 1, 2022

GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly...

Company Deals

Ribo Life Science Raises USD 40M in Series E1 Round for siRNA Drug Development

Fineline Cube Aug 1, 2022

China-based Suzhou Ribo Life Science Co., Ltd reportedly raised USD 40 million in a Series...

Company Deals

BridGene Biosciences Completes USD 38.5M Series B Round with China Funds

Fineline Cube Aug 1, 2022

U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5...

Company Deals Hospital

Basecare Medical Sells 35% Stake in Cellpro Biotech for USD 9.5M

Fineline Cube Aug 1, 2022

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based IVF specialist, will sell a 35%...

Company Drug

Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial

Fineline Cube Aug 1, 2022

China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical...

Company Deals Digital

Pica Partners with BrainCo to Launch ADHD Product in China

Fineline Cube Aug 1, 2022

Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with...

Hospital Policy / Regulatory

NHC Designates National Mental Illness Medical Centers in Beijing and Shanghai

Fineline Cube Aug 1, 2022

The National Healthcare Commission (NHC) announced the establishment of national mental illness medical centers, designating...

Company Drug

Innovent and Laekna Dose First Patient in Afuresertib and Tyvyt Study for PD-1 Resistant Tumors

Fineline Cube Aug 1, 2022

China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that...

Company Drug

Dongcheng Pharmaceutical Gets NMPA Green Light for PSMA PET Imaging Drug

Fineline Cube Aug 1, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced it has received approval from...

Company Drug

CanSino Biologics Launches Menhycia Meningococcal Vaccine in Six Provinces

Fineline Cube Aug 1, 2022

China-based CanSino Biologics (HKG: 6185) announced the launch of its ACYW135 Meningococcal Conjugate Vaccine (CRM197)...

Company Drug

Mabwell Bioscience Gets FDA Approval for Nectin-4 ADC 9MW2821 in Solid Tumors

Fineline Cube Aug 1, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received approval from the...

Company Drug

LaNova Medicines Gets FDA Green Light for LM-305 Myeloma Study

Fineline Cube Aug 1, 2022

Shanghai-based cancer therapy developer LaNova Medicines Ltd announced it has received approval from the U.S....

Posts pagination

1 … 588 589 590 … 611

Recent updates

  • Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
  • Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
  • AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
  • Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
  • Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.